vTv Therapeutics Inc. (VTVT)

Compare

15.40

-0.86

(-5.29%)

As of 12:00:13 PM EDT. Market Open.

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.

Zacks 17 days ago

SRPT

VTVT
-5.29%
GILD
VTv Therapeutics: Q4 Earnings Snapshot

On a per-share basis, the High Point, North Carolina-based company said it had a loss of 55 cents. The biopharmaceutical company posted revenue of $17,000 in the period. For the year, the company reported a loss of $18.5 million, or $3.20 per share.

Associated Press Finance 17 days ago

VTVT
-5.29%
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin be

GlobeNewswire 17 days ago

VTVT
-5.29%
FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes

Last July, the agency placed a hold on the trial due to a chromatographic signal detected in a human ADME study of the therapy.

Clinical Trials Arena 20 days ago

VTVT
-5.29%
vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial

The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.

GuruFocus.com 20 days ago

VTVT
-5.29%
FDA Lifts Clinical Hold-vTv Stock Jumps Nearly 28% on Diabetes Drug Progress

FDA clears vTv's cadisegliatin trial, prompting a 27.87% stock surge as the company fast-tracks pivotal studies

GuruFocus.com 21 days ago

VTVT
-5.29%
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for

GlobeNewswire 21 days ago

VTVT
-5.29%
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 2 months ago

VTVT
-5.29%
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon's two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, re

PR Newswire 3 months ago

VTVT
-5.29%
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference Presentation Date:December 4, 2024

GlobeNewswire 4 months ago

VTVT
-5.29%
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71%

vTv Therapeutics Inc. ( NASDAQ:VTVT ) shareholders should be happy to see the share price up 29% in the last week. But...

Simply Wall St. 4 months ago

VTVT
-5.29%
VTv Therapeutics: Q3 Earnings Snapshot

HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. VTVT) on Tuesday reported a loss of $4.8 million in its third quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 88 cents.

Associated Press Finance 4 months ago

VTVT
-5.29%
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate developments. "Our cadisegliatin program continues to show promise as a new oral adjunct therapy being investigated for improvement in glycemic control and reduction of

GlobeNewswire 4 months ago

VTVT
-5.29%
vTv Therapeutics Faces License Agreement Termination

vTv Therapeutics ( (VTVT) ) has issued an update. OnKure Therapeutics plans to terminate its License Agreement with vTv Therapeutics LLC, ending the development of the ppar-δ agonist program. This move, effective January 2025, might impact investors interested in the pharmaceutical collaborations and the future of vTv’s intellectual property ventures. Learn more about VTVT stock on TipRanks’ Stock Analysis page.

TipRanks 5 months ago

VTVT
-5.29%
VTv Therapeutics: Q2 Earnings Snapshot

HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. VTVT) on Thursday reported a loss of $5.2 million in its second quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 81 cents.

Associated Press Finance 7 months ago

VTVT
-5.29%
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today reported financial

GlobeNewswire 7 months ago

VTVT
-5.29%
FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks

vTv Therapeutics Inc. (NASDAQ:VTVT) stock is trading lower on Monday. The FDA has placed a clinical hold on the cadisegliatin clinical program, which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver-selective, glucokinase activator. The company says the drug candidate has been well-tolerated in over 500 subjects to date with up to six months of treatment. Related: Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today? Selectively acting o

Benzinga 8 months ago

VTVT
-5.29%
FDA places vTv Therapeutics’s cadisegliatin programme on clinical hold

The clinical hold was placed following the identification of an unresolved chromatographic signal in a recent human ADME study.

Clinical Trials Arena 8 months ago

VTVT
-5.29%
vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink

vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink

PREMIUM
MT Newswires 8 months ago

VTVT
-5.29%
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been

GlobeNewswire 8 months ago

VTVT
-5.29%

Performance Overview

Return	VTVT	S&P 500 (^GSPC)
YTD	+11.52%	-15.08%
1-Year	-38.84%	-4.03%
3-Year	-35.83%	+10.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

vTv Therapeutics Inc. (VTVT)

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

VTv Therapeutics: Q4 Earnings Snapshot

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes

vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial

FDA Lifts Clinical Hold-vTv Stock Jumps Nearly 28% on Diabetes Drug Progress

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71%

VTv Therapeutics: Q3 Earnings Snapshot

vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Faces License Agreement Termination

VTv Therapeutics: Q2 Earnings Snapshot

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks

FDA places vTv Therapeutics’s cadisegliatin programme on clinical hold

vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Performance Overview